Ask AI
ProCE Banner Series

Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs

This expert-led educational program provides insights into continuing education on the emerging PROTAC ER degraders in patients with HR+/HER2- metastatic breast cancer.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for medical oncologists, nurses, pharmacists, physician associates, and other healthcare professionals caring for patients with breast cancer.

All Events

Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs

Upcoming Events

October

29

2025

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Topics

Breast Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to enhance learners’ knowledge, confidence, and competence in understanding the emerging role of proteolysis-targeting chimera estrogen receptor (PROTAC ER) degraders in the evolving treatment landscape for patients with metastatic breast cancer in the post-CDK4/6 inhibitor setting.

Target Audience
This program is intended for medical oncologists, nurses, pharmacists, physician associates, and other healthcare professionals caring for patients with breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the current unmet needs in ER+/HER2- mBC and the role of biomarker testing, including ESR1 mutations

  • Differentiate the mechanisms of action between PROTAC ER degraders and other endocrine therapies

  • Evaluate current and emerging clinical data supporting the use of PROTAC ER degraders in patients with endocrine-resistant ER+/HER2- mBC

  • Apply expert-guided treatment strategies for integrating PROTAC ER degraders in clinical practice post-CDK4/6i therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-346-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.com to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Pfizer, Inc.

Arvinas

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191